SARS-CoV-2刺突蛋白抑制剂活性筛选方法研究进展

Recent advances in drug screening methods of SARS-CoV-2 spike protein

严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的新型冠状病毒感染(corona virus disease 2019,COVID-19)对全球公共卫生和经济造成了前所未有的影响。SARSCoV-2通过其表面的刺突蛋白与宿主细胞膜上的血管紧张素转换酶2相结合是入侵宿主细胞的关键步骤,以刺突蛋白为靶标的小分子药物成为抗SARS-CoV-2研究的热点。活性筛选是小分子药物研发的关键步骤。鉴于此,本文综述了SARS-CoV-2刺突蛋白小分子抑制剂的活性筛选方法,以期为靶向刺突蛋白的抗病毒药物研发提供参考。

The pandemic of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused a serious impact on global public health and the economy.SARS-CoV-2 infiltrates host cells via its surface spike protein,which binds to angiotensin-converting enzyme 2 on the host cell membrane.As a result,small molecules targeting spike protein have emerged as a hotspot in anti-SARS-CoV-2 drug research.Activity screening is an important step in seeking small molecule drugs.Therefore,this article aims to review the biological activity evaluation methods of small molecule inhibitors targeting SARS-CoV-2 spike protein,with the goal of laying the foundation for the discovery of new anti-SARS-CoV-2 drugs.